Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model

Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma

(2014) Qi Li et al.   CANCER SCIENCE

A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody

(2013) S. Abe et al.   JOURNAL OF IMMUNOLOGY

Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas

(2013) Koji Shindo et al.   Molecular Cancer

Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo

(2012) Miki Tongu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity

(2012) Mika Kato Kaneko et al.   CANCER SCIENCE

Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus

(2012) Sebastian F. Schoppmann et al.   CLINICAL & EXPERIMENTAL METASTASIS

Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer

(2012) Ivan Shevchenko et al.   INTERNATIONAL JOURNAL OF CANCER

Podoplanin-Positive Fibroblasts Enhance Lung Adenocarcinoma Tumor Formation: Podoplanin in Fibroblast Functions for Tumor Progression

(2011) A. Hoshino et al.   CANCER RESEARCH

Advances in the assessment and control of the effector functions of therapeutic antibodies

(2011) Xu-Rong Jiang et al.   NATURE REVIEWS DRUG DISCOVERY

The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice

(2010) Trung The Van et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

(2010) R. Hassan et al.   CLINICAL CANCER RESEARCH

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

(2010) Yukinari Kato et al.   NUCLEAR MEDICINE AND BIOLOGY

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells

(2009) Koji Kawaguchi et al.   CARCINOGENESIS

Malignant Pleural Mesothelioma

(2009) Mandira Ray et al.   CHEST

E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles

(2009) K. Ikuta et al.   CLINICAL CANCER RESEARCH

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

(2009) A. Scherpereel et al.   EUROPEAN RESPIRATORY JOURNAL

Expression of Soluble Vascular Endothelial Growth Factor Receptor-1 in Human Monocyte-Derived Mature Dendritic Cells Contributes to Their Antiangiogenic Property

(2009) M. Kishuku et al.   JOURNAL OF IMMUNOLOGY

Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism

(2009) G. V. Shurin et al.   JOURNAL OF IMMUNOLOGY

Directed Expression of Transgenes to Alveolar Type I Cells in the Mouse

(2008) Jeff N. Vanderbilt et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody

(2008) Wei Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Characterization of Anti-podoplanin Monoclonal Antibodies: Critical Epitopes for Neutralizing the Interaction Between Podoplanin and CLEC-2

(2008) Satoshi Ogasawara et al.   HYBRIDOMA

Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma

(2008) Akikazu Kawase et al.   INTERNATIONAL JOURNAL OF CANCER

Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells

(2008) Wei Wang et al.   LUNG CANCER